The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksE-therapeutics Regulatory News (ETX)

Share Price Information for E-therapeutics (ETX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.40
Bid: 9.00
Ask: 9.35
Change: -0.625 (-6.38%)
Spread: 0.35 (3.889%)
Open: 9.45
High: 9.60
Low: 9.40
Prev. Close: 9.80
ETX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Results of conditional Fundraise to raise £22.5m

14 May 2021 07:00

RNS Number : 6093Y
e-Therapeutics plc
14 May 2021
 

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED TO CONSTITUTE INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) NO. 596/2014 (AS AMENDED) AS IT FORMS PART OF THE DOMESTIC LAW OF THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 (AS AMENDED). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN ARE FOR INFORMATION PURPOSES ONLY AND DO NOT CONSTITUTE AN OFFER OF SECURITIES IN ANY JURISDICTION. PLEASE REFER TO THE IMPORTANT NOTICES SECTION AT THE END OF THIS ANNOUNCEMENT.

NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE PROHIBITED BY ANY APPLICABLE LAW.

14 May 2021

e-therapeutics plc 

Results of conditional Fundraise to raise £22.5 million

e-therapeutics plc (AIM: ETX.L, "e-therapeutics'" or "the Company") announces, further to the announcement made by the Company on 13 May 2021 (the "Launch Announcement"), the successful completion of a Placing, Subscription and Retail Offer via PrimaryBid (together the "Fundraise") conditionally raising gross proceeds of £22.5 million for the Company. In total, 93,750,000 new Ordinary Shares will be issued pursuant to the Fundraise at the Placing Price of 24 pence per new Ordinary Share.

Details of the Fundraise

Pursuant to the Placing, a total of 81,208,333 Placing Shares will be issued, raising gross proceeds of £19.49 million.

Pursuant to the Subscription, a total of 8,708,334 Subscription Shares will be issued, raising gross proceeds of £2.09 million.

Pursuant to the Retail Offer, a total of 3,833,333 Retail Shares will be issued, raising gross proceeds of £0.92 million.

The Fundraise (details of which were provided in the Launch Announcement) is conditional on, inter alia, shareholder approval being received at the Annual General Meeting ("AGM") of the Company which is expected to be held on or around 16 June 2021. A notice convening the AGM will be announced and posted to shareholders in due course.

An application for Admission of the Placing Shares, Subscription Shares and Retail Shares will be made in due course with such shares expected to be admitted to trading on AIM on or around 17 June 2021, conditional upon shareholder approval at the AGM. The new Ordinary Shares will rank pari passu in all respects with the Company's existing Ordinary Shares at that time. 

Total Voting Rights

Following the issue of the Placing Shares, Subscription Shares and Retail Shares, the Company will have 514,523,546 Ordinary Shares of 0.1 pence each in issue.

Defined terms in this announcement shall have the same meaning as in the Launch Announcement unless otherwise specified.

 

Enquiries:

e-therapeutics plc

 

Ali Mortazavi, CEO

Karl Keegan, CFO

Laura Roca-Alonso, CBO

Tel: +44 (0)1993 883 125 www.etherapeutics.co.uk

 

 

SP Angel Corporate Finance LLP

Tel: +44(0)20 3470 0470

Nominated Adviser and Broker

 

Matthew Johnson/Caroline Rowe (Corporate Finance)

 

Vadim Alexandre/Rob Rees (Corporate Broking)

 

 

IMPORTANT NOTICES

THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE OR FORM ANY PART OF AN OFFER TO SELL OR ISSUE, OR A SOLICITATION OF AN OFFER TO BUY, SUBSCRIBE FOR OR OTHERWISE ACQUIRE ANY SECURITIES IN THE UNITED STATES (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA (COLLECTIVELY, THE "UNITED STATES")), AUSTRALIA, CANADA, THE REPUBLIC OF SOUTH AFRICA, JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH OFFER OR SOLICITATION WOULD BE UNLAWFUL OR TO ANY PERSON TO WHOM IT IS UNLAWFUL TO MAKE SUCH OFFER OR SOLICITATION. NO PUBLIC OFFERING OF THE PLACING SHARES IS BEING MADE IN ANY SUCH JURISDICTION. THIS ANNOUNCEMENT HAS NOT BEEN APPROVED BY THE LONDON STOCK EXCHANGE. ANY FAILURE TO COMPLY WITH THESE RESTRICTIONS MAY CONSTITUTE A VIOLATION OF THE SECURITIES LAWS OF SUCH JURISDICTIONS.

This Announcement is not for public release, publication, distribution or forwarding, in whole or in part, directly or indirectly, in or into the United States, Australia, Canada, the Republic of South Africa, Japan or any other jurisdiction in which such release, publication, distribution or forwarding would be unlawful.

This Announcement is not for publication or distribution, directly or indirectly, in or into the United States. This announcement is not an offer of securities for sale into the United States. The securities referred to herein have not been and will not be registered under the US Securities Act of 1933, as amended, (the "Securities Act"), and may not be offered or sold in the United States, except pursuant to an applicable exemption from registration. No public offering of securities is being made in the United States.

The distribution of this Announcement and the Placing and/or the offer or sale of the Placing Shares in certain jurisdictions may be restricted by law. No action has been taken by the Company or SP Angel Corporate Finance LLP ("SP Angel") or any of their respective affiliates, or any of its or their respective directors, officers, partners, employees, advisers or agents (collectively, "Representatives") that would, or is intended to, permit an offer of the Placing Shares or possession or distribution of this Announcement or any other offering or publicity material relating to such Placing Shares in any jurisdiction where action for that purpose is required. Persons into whose possession this Announcement comes are required by the Company and SP Angel to inform themselves about and to observe any restrictions contained in this Announcement. Persons (including, without limitation, nominees and trustees) who have a contractual or other legal obligation to forward a copy of this Announcement should seek appropriate advice before taking any action. Persons distributing any part of this Announcement must satisfy themselves that it is lawful to do so.

This Announcement is directed at and is only being distributed to: (a) in member states of the European Economic Area, persons who are "qualified investors", as defined in Article 2(e) of Regulation (EU) 2017/1129 (the "EU Prospectus Regulation") ("EU Qualified Investors"), (b) in the United Kingdom, Qualified Investors who (i) have professional experience in matters relating to investments and who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order") or are high net worth companies, unincorporated associations or partnerships or trustees of high value trusts as described in Article 49(2) of the Order and (ii) are "qualified investors" within the meaning of Article 2(e) of Regulation (EU) 2017/1129 as amended, as it forms part of UK law as retained EU law as defined in, and by virtue of, the European Union (Withdrawal) Act 2018 (as amended) (the "UK Prospectus Regulation") ("UK Qualified Investors"), and (c) otherwise, persons to whom it may otherwise lawfully be communicated (each such person in (a), (b) and (c), a "Relevant Person"). No other person should act on or rely on this Announcement and persons distributing this Announcement must satisfy themselves that it is lawful to do so. By accepting the terms of this Announcement, you represent and agree that you are a Relevant Person. This Announcement must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this Announcement or the Placing relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.

No prospectus or admission document will be made available in any jurisdiction in connection with the matters contained or referred to in this Announcement or the Placing and no such prospectus is required (in accordance with the EU Prospectus Regulation or the UK Prospectus Regulation) to be published.

Certain statements in this Announcement are forward-looking statements with respect to the Company's expectations, intentions and projections regarding its future performance, strategic initiatives, anticipated events or trends and other matters that are not historical facts and which are, by their nature, inherently predictive, speculative and involve risks and uncertainty because they relate to events and depend on circumstances that may or may not occur in the future. All statements that address expectations or projections about the future, including statements about operating performance, strategic initiatives, objectives, market position, industry trends, general economic conditions, expected expenditures, expected cost savings and financial results are forward ‐ looking statements. Any statements contained in this Announcement that are not statements of historical fact are, or may be deemed to be, forward ‐ looking statements. These forward-looking statements, which may use words such as "aim", "anticipate", "believe", "could", "intend", "estimate", "expect", "may", "plan", "project" or words or terms of similar meaning or the negative thereof, are not guarantees of future performance and are subject to known and unknown risks and uncertainties. There are a number of factors including, but not limited to, commercial, operational, economic and financial factors, that could cause actual results, financial condition, performance or achievements to differ materially from those expressed or implied by these forward ‐ looking statements. Many of these risks and uncertainties relate to factors that are beyond the Company's ability to control or estimate precisely, such as changes in taxation or fiscal policy, future market conditions, currency fluctuations, the behaviour of other market participants, the actions of governments or governmental regulators, or other risk factors, such as changes in the political, social and regulatory framework in which the Company operates or in economic or technological trends or conditions, including inflation, recession and consumer confidence, on a global, regional or national basis. Given those risks and uncertainties, readers are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date of this Announcement. Each of the Company and SP Angel expressly disclaims any obligation or undertaking to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise unless required to do so by applicable law or regulation.

SP Angel is authorised and regulated in the United Kingdom by the Financial Conduct Authority ("FCA"). SP Angel is acting exclusively for the Company and for no one else in connection with the Placing and will not regard any other person (whether or not a recipient of this Announcement) as a client in relation to the Placing or any other matter referred to in this Announcement and will not be responsible to anyone other than the Company for providing the protections afforded to its clients or for giving advice in relation to the Placing or any other matter referred to in this Announcement.

This Announcement is being issued by and is the sole responsibility of the Company. No representation or warranty, express or implied, is or will be made as to, or in relation to, and no responsibility or liability is or will be accepted by or on behalf of SP Angel (apart from the responsibilities or liabilities that may be imposed by the Financial Services and Markets Act 2000, as amended ("FSMA") or the regulatory regime established thereunder) or by their respective affiliates or any of their respective Representatives as to, or in relation to, the accuracy, adequacy, fairness or completeness of this Announcement or any other written or oral information made available to or publicly available to any interested party or its advisers or any other statement made or purported to be made by or on behalf of SP Angel or any of their respective affiliates or any of their respective Representatives in connection with the Company, the Placing Shares or the Placing and any responsibility and liability whether arising in tort, contract or otherwise therefor is expressly disclaimed. No representation or warranty, express or implied, is made by SP Angel or any of their respective affiliates or any of their respective Representatives as to the accuracy, fairness, verification, completeness or sufficiency of the information or opinions contained in this Announcement or any other written or oral information made available to or publicly available to any interested party or its advisers, and any liability therefor is expressly disclaimed. The information in this Announcement is subject to change.

The information in this Announcement may not be forwarded or distributed to any other person and may not be reproduced in any manner whatsoever. Any forwarding, distribution, reproduction or disclosure of this Announcement, in whole or in part, is unauthorised. Failure to comply with this directive may result in a violation of the Securities Act or the applicable laws of other jurisdictions.

This Announcement does not constitute a recommendation concerning any investor's options with respect to the Placing. Recipients of this Announcement should conduct their own investigation, evaluation and analysis of the business, data and other information described in this Announcement. This Announcement does not identify or suggest, or purport to identify or suggest, the risks (direct or indirect) that may be associated with an investment in the Placing Shares. The price and value of securities can go down as well as up and investors may not get back the full amount invested upon the disposal of the shares. Past performance is not a guide to future performance. The contents of this Announcement are not to be construed as legal, business, financial or tax advice. Each investor or prospective investor should consult with his or her or its own legal adviser, business adviser, financial adviser or tax adviser for legal, business, financial or tax advice.

Any indication in this Announcement of the price at which the Company's shares have been bought or sold in the past cannot be relied upon as a guide to future performance. Persons needing advice should consult an independent financial adviser. No statement in this Announcement is intended to be a profit forecast or profit estimate for any period and no statement in this Announcement should be interpreted to mean that earnings, earnings per share or income, cash flow from operations or free cash flow for the Company for the current or future financial periods would necessarily match or exceed the historical published earnings, earnings per share or income, cash flow from operations or free cash flow for the Company.

All offers of the Placing Shares have been made pursuant to an exemption under the EU Prospectus Regulation and the UK Prospectus Regulation from the requirement to produce a prospectus. This Announcement is being distributed and communicated to persons in the United Kingdom only in circumstances in which section 21(1) of FSMA does not apply.

The Placing Shares to be issued pursuant to the Placing will not be admitted to trading on any stock exchange other than AIM, a market operated by the London Stock Exchange.

Neither the content of the Company's website (or any other website) nor the content of any website accessible from hyperlinks on the Company's website (or any other website) is incorporated into, or forms part of, this Announcement.

This Announcement has been prepared for the purposes of complying with applicable law and regulation in the United Kingdom and the information disclosed may not be the same as that which would have been disclosed if this Announcement had been prepared in accordance with the laws and regulations of any jurisdiction outside the United Kingdom.

SP Angel and its affiliates may have engaged in transactions with, and provided various commercial banking, investment banking, financial advisory transactions and services in the ordinary course of their business with the Company and/or its affiliates for which they would have received customary fees and commissions. SP Angel and its affiliates may provide such services to the Company and/or its affiliates in the future.

Solely for the purposes of the product governance requirements contained within: (a) EU Directive 2014/65/EU on markets in financial instruments, as amended ("MiFID II"); (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c) local implementing measures (together, the "MiFID II Product Governance Requirements"), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any 'manufacturer' (for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the Placing Shares have been subject to a product approval process, which has determined that such Placing Shares are: (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in MiFID II; and (ii) eligible for distribution through all distribution channels as are permitted by MiFID II (the "Target Market Assessment"). Notwithstanding the Target Market Assessment, distributors should note that: the price of the Placing Shares may decline and investors could lose all or part of their investment; the Placing Shares offer no guaranteed income and no capital protection; and an investment in the Placing Shares is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the Placing. Furthermore, it is noted that, notwithstanding the Target Market Assessment, SP Angel will only procure investors who meet the criteria of professional clients and eligible counterparties.

For the avoidance of doubt, the Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of MiFID II; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the Placing Shares. Each distributor is responsible for undertaking its own target market assessment in respect of the Placing Shares and determining appropriate distribution channels.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IOEDBGDUDUBDGBX
Date   Source Headline
29th Apr 20242:09 pmRNSResult of General Meeting
10th Apr 20247:00 amRNSProposed Fundraise of £28.9m and Cancellation
31st Jan 20244:30 pmRNSTotal Voting Rights
24th Jan 202410:04 amRNSExercise of Options and Issue of Equity
16th Jan 20247:00 amRNSBusiness Update
9th Jan 20244:04 pmRNSDirector Dealing and Issue of Equity
27th Dec 20237:00 amRNSUpdate on OTCQX Market Listing
13th Nov 20239:05 amEQSEdison issues update on e-therapeutics (ETX): More to come in RNAi therapy discovery
2nd Nov 20237:00 amRNSStrategic RWE collaboration with Arcturis
26th Oct 20237:38 amRNSInterim results for the six months to 31 July 2023
19th Oct 20239:54 amRNSNotice of Interim Results
20th Sep 20237:00 amRNSSenior Management Update
7th Sep 202311:47 amRNSExercise of Options and Issue of Equity
31st Jul 20234:30 pmRNSTotal Voting Rights
18th Jul 20234:20 pmRNSResult of Annual General Meeting
6th Jul 20235:27 pmRNSDirector Dealing and Issue of Equity
30th Jun 20237:00 amRNSInvestor Presentation
26th Jun 20237:00 amRNSNotice of Investor Presentation
11th May 20237:00 amRNSNotice of AGM and Posting of Annual Report
4th May 20237:00 amRNSFinal results for the year ended 31 January 2023
28th Apr 20234:30 pmRNSTotal Voting Rights
27th Apr 20237:00 amRNSNotification of Full Year Results Date
28th Mar 20233:57 pmRNSExercise of Options and Issue of Equity
21st Feb 20234:35 pmRNSPrice Monitoring Extension
20th Feb 202310:19 amRNSDirector/PDMR Shareholding
7th Feb 20237:00 amRNSFiling of four patent applications
31st Jan 20237:00 amRNSTotal Voting Rights
4th Jan 20233:15 pmRNSDirector Dealing and Issue of Equity
29th Dec 20224:40 pmRNSSecond Price Monitoring Extn
29th Dec 20224:35 pmRNSPrice Monitoring Extension
20th Dec 20224:35 pmRNSPrice Monitoring Extension
31st Oct 20227:00 amRNSTotal Voting Rights
12th Oct 20223:12 pmRNSHolding(s) in Company
11th Oct 202210:42 amRNSHolding(s) in Company
10th Oct 20228:03 amRNSHolding(s) in Company
30th Sep 20227:00 amRNSInterim results for the six months to 31 July 2022
30th Sep 20227:00 amRNSFundraise of £13.5 million by way of Subscription
26th Sep 20224:40 pmRNSSecond Price Monitoring Extn
26th Sep 20224:36 pmRNSPrice Monitoring Extension
1st Aug 20227:00 amRNSFiling of eight patent applications
29th Jul 20227:00 amRNSTotal Voting Rights
20th Jul 202210:39 amRNSResult of Annual General Meeting
6th Jul 20227:00 amRNSNotice to Shareholders - AGM Virtual Access
5th Jul 20227:00 amRNSDirector Dealing and Issue of Equity
17th May 20227:00 amRNSNotice of AGM and Posting of Annual Report
4th May 20227:00 amRNSFinal results for the year ended 31 January 2022
27th Apr 20227:00 amRNSNotification of Full Year Results Date
12th Apr 20227:00 amRNSKey Milestone Achieved on Galapagos Collaboration
5th Apr 20227:00 amRNSImmuno-Oncology Research Collaboration with iTeos
16th Feb 20224:41 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.